Jazz Pharmaceuticals has announced that Kathryn Falberg, executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests. Ms. Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period.
Matthew Young, senior vice president of corporate development at Jazz Pharmaceuticals, has been appointed senior vice president and CFO, reporting to Bruce Cozadd, chairman and chief executive officer, as of the effectiveness of Ms. Falberg's resignation. Mr. Young joined Jazz Pharmaceuticals in early 2013.
“I would like to thank Kate for her significant contributions to the growth and success of Jazz Pharmaceuticals over the past four years. Kate has greatly expanded and strengthened the company's finance organization, as well as our strategy, corporate development, external communications and information technology functions, and has played a role in developing and implementing the company's growth strategy and in creating value for shareholders," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "Matt has played a critical role in helping Jazz Pharmaceuticals execute on our since he joined the company, including successfully leading efforts to complete two transactions. I look forward to working with Matt in his new role. His knowledge of our business, strong leadership skills and extensive experience in life sciences investment banking position him well for success as our CFO."
Prior to joining Jazz Pharmaceuticals, Mr. Young worked in investment banking for approximately 20 years. His most recent investment banking role was as the Managing Director in Global Healthcare and Co-Head of Life Sciences at Barclays Capital. Previously, Mr. Young was head of U.S. Life Sciences at Citigroup, and, prior to that, was head of West Coast Healthcare and directed the life sciences coverage effort at Lehman Brothers. He has worked on numerous mergers and acquisitions, corporate finance and other transactions during his career. Mr. Young received his B.S. in Economics and his M.B.A. from the Wharton School of Business.